Innate Pharma SA ( (FR:IPH) ) just unveiled an update.
Innate Pharma announced a conference call and webcast scheduled for March 27, 2025, to discuss its full-year 2024 financial results. The event will feature key executives from the company, highlighting its ongoing commitment to transparency and stakeholder engagement. This announcement underscores Innate Pharma’s strategic focus on maintaining investor relations and providing updates on its financial performance, which is crucial for its positioning in the biotechnology industry.
More about Innate Pharma SA
Innate Pharma S.A. is a global clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company employs innovative approaches to harness the innate immune system through multi-specific NK Cell Engagers, Antibody Drug Conjugates, and monoclonal antibodies. Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca to accelerate innovation and research, and is listed on Euronext Paris and Nasdaq.
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $172.8M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.